(AsiaGameHub) -   Taking place from May 18-20 at the Novotel Madrid Center, the AffPapa Conference Madrid 2026 calls upon industry experts to gather in Spain's capital for two days filled with dialogue, industry insights, and extensive networking driven by affiliates. The schedule features a robust lineup of panel discussions, networking chances, and various side events, all curated to unite affiliates, operators, and B2B suppliers. Discover what awaits you at the AffPapa Conference Madrid 2026. May 18: Pre-conference events To enhance the experience beyond the main exhibition area, the AffPapa Conference Madrid kicks off with a full day of side activities aimed at gathering attendees prior to the start of the hectic conference schedule. These activities include: Running Club sponsored by Hybrid Interaction Padel tournament sponsored by Bazoom Guided tour of the Santiago Bernabéu and Real Madrid Museum sponsored by JoinAff The evening prior to the conference will wind down with an Opening Networking Event, offering beverages and a casual atmosphere for networking before the main proceedings commence. May 19-20: Discussions, workshops, and further networking opportunities Across the two days, the AffPapa Conference Madrid schedule provides a variety of interactive engagements focused on sharing insights and networking, such as: Panel discussions addressing current trends in affiliate marketing and iGaming. An AI Workshop hosted by createIT. Speed-dating sessions featuring one-minute rotations to link affiliates with operators. Networking drinks following the conclusion of each conference day. To ensure the highest practical value for participants, the panels concentrate on the most pertinent subjects in iGaming currently, spanning business strategy, collaborations between operators and affiliates, regulatory issues, market movements, blockchain, cryptocurrency, NFTs, the Spanish iGaming sector, and additional topics. Additionally, the schedule includes a practical AI workshop centered on automation and operational efficiency, tailored for iGaming specialists seeking tangible methods to utilize AI and automation to achieve genuine operational outcomes. This year, exhibitors at the AffPapa Conference Madrid will also have the choice to display their brands via fully customizable stands or opt for a standard booth created by AffPapa. AffPapa iGaming Awards The final day of the conference will culminate in the AffPapa iGaming Awards 2026, which will highlight its unique theme “The Test of Time” and four newly launched exclusive categories. To celebrate the conclusion of the largest edition of the AffPapa Conference thus far, anticipated to draw more than 1,500 participants, the flagship event will finish with an official closing party, headlined by international EDM DJ and producer Kryoman. The schedule is regularly updated on the official AffPapa Conference Madrid website, where visitors can view the complete program, secure their place, and investigate sponsorship possibilities. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   BoscaSports, the Irish technology firm revolutionizing live betting information for racecourses and betting operators globally, has finalized its acquisition of UK-based 2DB, an integrated video streaming and data solutions business specializing in digital display technology. This transaction positions the combined entity as a leading provider of LBO display technology, video streaming, and data-driven distribution services in the market. The acquisition received support through a loan facility from Allied Irish Bank (AIB), signifying strong confidence in BoscaSports’ performance, strategy, and long-term potential. Eugene Mitchell, CEO of BoscaSports, said: This acquisition is truly transformative for BoscaSports. Merging our strengths with 2DB’s integrated video streaming and data solutions greatly improves our technological foundation, broadens our distribution footprint, and boosts the value we can provide to racecourses, operators, and bettors globally. We are proud to represent an Irish tech success story and appreciate the backing from AIB and Racecourse Media Group (RMG) as we move into this next stage of expansion. RMG, a minority investor in BoscaSports since its inception, has increased its investment to facilitate the deal and ensure the company has ample resources for future innovation. Nick Mills, CEO of Racecourse Media Group, said: BoscaSports has been a dependable partner from the very start, and we are pleased to endorse this acquisition. Ensuring the durability of our investment and enabling BoscaSports to offer long-term, leading-edge solutions is vital for the entire racing industry and enhances shareholder value for our racecourses. 2DB is a UK-based software expert, delivering integrated video streaming and real-time data solutions that drive digital display systems throughout the gaming industry. The company is highly regarded by major international brands for its dependability, technical proficiency, and extensive experience. Steve Boffo, Managing Director of 2DB Ltd, said: We are thrilled to announce that 2DB has been acquired by BoscaSports. This represents an ideal cultural and strategic alignment, and we are prepared to move forward swiftly for the benefit of our team and our customers. The incorporation of 2DB will result in a doubling of BoscaSports’ team, allowing the company to speed up product development, broaden its international presence, and further improve video, data, and display solutions across on-course, retail, and online betting platforms. Pat Horgan, Head of Business Banking, Capital Markets, AIB, said: At AIB, we take pride in backing Ireland’s homegrown technology companies as they expand globally. Their innovation stimulates economic growth, generates high-value employment, and solidifies Ireland’s standing as a prominent global technology hub. Bosca Technologies perfectly illustrates this ambition, demonstrating how pioneering innovation, robust strategic alliances, and a global outlook can lead to success on the international stage. BoscaSports presently supplies live betting data to retail displays at all 86 racecourses throughout the UK and Ireland, and the Group will now extend its operations to 12 countries, including Italy, Sri Lanka, Cyprus, Malta, Morocco, and the UAE. The consolidated client roster in the UK and Ireland now encompasses leading operators like Flutter’s brands, such as Paddy Power, alongside Entain, Britbet, William Hill, Boyle Sports, UK Tote, Tote Ireland, and the independent sector. Furthermore, the company has secured several notable new contracts over the past year, involving Abu Dhabi Turf Club/Momentum, MST (Italy), SOREC in Morocco, Ascot Racecourse, and BetMakers/Greyhound Racing Ireland. BoscaSports’ revenue saw an approximate 40% increase in the last 12 months, highlighting the robustness of its technology and its lucrative, expandable business model. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, Representative Director: Prashant Nikam, “MSD”), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG® (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2α) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.This application is based on the results of the Phase 3 LITESPARK-011 trial evaluating the dual regimen of LENVIMA plus WELIREG for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. The data from this trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in February 2026. At a pre-specified interim analysis with a median follow-up of 29.0 months (range, 19.3-49.2), the LENVIMA plus WELIREG combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the primary endpoints, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. The safety profile of this combination was consistent with those reported for each agent administered as monotherapy, and no new safety signals were identified.In 2022, approximately 435,000 people worldwide were newly diagnosed with kidney cancer, and about 156,000 people died from the disease. 1 In Japan, it is estimated that roughly 21,000 people were newly diagnosed and about 7,000 died in 2022.2 RCC accounts for approximately 85% of kidney cancers3, and the five-year survival rates for patients with stage III and IV RCC have been reported as 63%–78% and 27%–28%4, respectively, indicating that the disease still has a high unmet medical needs.LENVIMA is approved in combination with KEYTRUDA ® (pembrolizumab) in Japan for the first-line treatment of unresectable or metastatic RCC. WELIREG is approved in Japan for the treatment of unresectable or metastatic RCC that has progressed following cancer chemotherapy. Additionally, supplemental New Drug Applications (sNDA) for the LENVIMA and WELIREG combination therapy for the treatment of adult patients with advanced RCC with a clear cell component following a PD-1 or PDL1 inhibitor has been accepted by the U.S. Food and Drug Administration (FDA), with a PDUFA (Prescription Drug User Fee Act) target action date set for October 4, 2026.Eisai and MSD have been collaborating through the provision of information on LENVIMA in Japan since October 2018, and will work together to expedite the maximization of contribution to patients with cancer.About LENVIMA (lenvatinib)LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1- 4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.Thyroid cancer- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable thyroid cancerThe United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)Hepatocellular carcinoma- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable hepatocellular carcinomaThe United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy- Indication in combination with KEYTRUDA (generic name: pembrolizumab) and transarterial chemoembolization (Approved in China)Thymic carcinoma- Indication as monotherapy (Approved in Japan)Japan: Unresectable thymic carcinomaRenal cell carcinoma (In Europe other than the United Kingdom, the agent was launched under the brand name Kisplyx®)- Indication in combination with everolimus(Approved mainly in the United States, Europe and Asia) The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapyEurope: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Radically unresectable or metastatic renal cell carcinomaThe United States: The first-line treatment of adult patients with advanced renal cell carcinomaEurope: The first-line treatment of adult patients with advanced renal cell carcinomaEndometrial carcinoma- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapyThe United States: The treatment of patients with advanced endometrial carcinoma that is pMMR or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiationEurope: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery.About WELIREG (belzutifan)WELIREG, Merck & Co., Inc., Rahway, NJ, USA’s, known as MSD outside of the United States and Canada, first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule designed to reduce transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG aims to disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival. WELIREG has demonstrated antitumor activity in certain von Hippel-Lindau (VHL) diseaseassociated tumors, renal cell carcinoma and in pheochromocytoma or paraganglioma. As part of a broader clinical program, Merck & Co., Inc., Rahway, NJ, USA continues to research WELIREG monotherapy and combination approaches for people with genitourinary, breast and gynecologic cancers across a range of treatment settings to further define where HIF-2α inhibition may provide clinical benefit and to better understand which patients are most likely to respond. WELIREG has been approved in Japan for the treatment of certain von Hippel–Lindau (VHL) disease–associated tumors, as well as for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.LITESPARK-011 ResultsData from LITESPARK-011 (ClinicalTrials.gov, NCT04586231) were presented at the ASCO GU Symposium held in February 2026. LITESPARK-011 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04586231) evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced clear cell RCC that has progressed on or after anti-PD-1/L1 therapy. The dual primary endpoints are progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR), and overall survival (OS). Secondary endpoints include objective response rate (ORR) per RECIST v1.1 as assessed by BICR, duration of response (DOR) per RECIST v1.1 as assessed by BICR, and safety. The trial enrolled 747 patients who were randomized to receive WELIREG (120 mg orally once daily) plus LENVIMA (20 mg orally once daily) or cabozantinib (60 mg orally once daily).At a pre-specified second interim analysis with a median follow-up of 29.0 months (range, 19.3- 49.2), WELIREG plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. For WELIREG plus LENVIMA, the median PFS was 14.8 months (95% CI, 11.2-16.6) versus 10.7 months (95% CI, 9.2-11.1) for cabozantinib. A trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was also observed for WELIREG plus LENVIMA (HR=0.85 [95% CI, 0.68-1.05]; p=0.06075). The median OS was 34.9 months (95% CI, 27.5-NR) for WELIREG plus LENVIMA versus 27.6 months (95% CI, 24.0-31.4) for cabozantinib. The trial is continuing, and OS will be evaluated at a subsequent analysis per the clinical trial protocol. Regarding secondary endpoints, at the first interim analysis with a median follow-up of 19.6 months (range, 9.9-39.8), WELIREG plus LENVIMA met ORR, demonstrating a statistically significant improvement compared to cabozantinib. A confirmed ORR of 52.6% (95% CI, 47.3-57.7) was observed for WELIREG plus LENVIMA versus 39.6% (95% CI, 34.6-44.8) for cabozantinib. At the second interim analysis with a median follow-up of 29.0 months, the median DOR was 23.0 months (95% CI, 2.0-44.3+) for WELIREG plus LENVIMA versus 12.3 months (95% CI, 1.8+-35.9+) for cabozantinib. WELIREG plus LENVIMA was administered to 370 patients and cabozantinib was administered to 371 patients. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 71.6% of patients receiving WELIREG plus LENVIMA versus 65.8% of patients receiving cabozantinib. Adverse events led to treatment discontinuation in 11.1% of patients receiving WELIREG plus LENVIMA and in 11.3% of patients receiving cabozantinib, respectively. Serious adverse events were observed in 51.6% of patients receiving WELIREG plus LENVIMA versus 43.9% of patients receiving cabozantinib, and AEs led to death in 5.4% of patients (two were treatment-related: thrombotic microangiopathy [n=1] and pneumonitis [n=1]) versus 3.2% (one was treatment-related: hemoptysis [n=1]) of patients, respectively.About the Eisai and Merck & Co., Inc., Rahway, NJ, USA Strategic CollaborationIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, and HIF-2α inhibitor, WELIREG.Eisai’s focus on cancerEisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “microenvironment”, “protein integrity and homeostasis”, and “cell lineage and cell differentiation” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.6. About EisaiEisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (U.S. and global), LinkedIn (for U.S. and EMEA) and Facebook (global).Merck & Co., Inc., Rahway, NJ, USA’s Focus on CancerEvery day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncologyAbout MSDAt MSD (the name by which Merck & Co., Inc., Rahway, NJ, USA, is known outside of the United States and Canada), we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.co.jp and connect with us on Facebook, Twitter, and YouTube.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf, accessed 27 Mar 2026.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/392-japan-fact-sheet.pdf, accessed 27 Mar 2026.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. 2025; 2026 Version 1. Rose TL and Kim WY. Renal cell carcinoma: a review. JAMA. 2024 Sep 24;332(12):1001– 10.Media InquiriesEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120MSD K.K.Communications DivisionTatsuro MuraseTEL: +81 (0)70-8700-0112 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and MUFG Bank, Ltd. (“MUFG Bank”), a consolidated subsidiary of Mitsubishi UFJ Financial Group, Inc. (TYO: 8306, “MUFG”) today announced a new Memorandum of Understanding (MoU) to expand NextGen, their business co-creation model. Building on their collaboration launched in May 2024*1 and further developed as announced in May 2025*2 , NextGen combines Hitachi’s technology and operational expertise with MUFG’s financial capabilities to accelerate the transition to decarbonized mobility.*1 MUFG’s Business Co-Creation and Investment into UK Battery as a Service project by Hitachi ZeroCarbon May 2024*2 Hitachi ZeroCarbon and MUFG unite technology expertise with financial support to accelerate fleet electrification May 2025NextGen was initially validated through a UK pilot project with First Bus, where the parties collaborated via a special purpose vehicle (SPV) to support the procurement and operation of electrification assets under a Battery-as-a-Service model. This expanded MoU extends NextGen beyond battery-focused structures, enabling broader and more scalable deployment across additional markets outside the UK and across a wider range of asset classes. These include emobility assets such as electric vehicles and charging infrastructure, associated energy management systems, and potentially extending to energy hubs supporting industrial assets, power grids and data centers.Hitachi and MUFG Bank will also develop and scale SPV structures to finance decarbonized mobility assets for fleet and transport operators. This approach removes capital constraints and accelerates implementation, enabling operators to focus on their core transport services. From Hitachi’s side, the initiative is led by its Strategic SIB Business Unit, bringing together expertise from across Hitachi including Hitachi Energy, as ‘One Hitachi’. Hitachi will also provide managed services for asset performance and lifecycle optimization, supported by data-driven solutions from Hitachi ZeroCarbon. Through this initiative, Hitachi aims to further advance and streamline mobility and charging infrastructure operations by expanding HMAX by Hitachi, a suite of next-generation solutions that embodies Lumada 3.0, differentiated by deep domain knowledge and AI.Electrifying commercial transport at pace will require an unprecedented deployment of vehicles, charging and energy infrastructure - alongside innovative financing models to support it. Global investment in electrified transport reached around US$750 billion in 2024, making it the largest segment of the energy transition worldwide*3 - yet many fleet operators face limited access to capital and the operational complexity of transitioning at scale. Against this backdrop, Hitachi and MUFG Bank aim to expand NextGen as a repeatable model to accelerate implementation by combining structured asset financing with managed services and data-driven optimization.*3 Sources: BloombergNEF’s Energy transition Investment Trends 2025In demonstration of the expanded pipeline, Hitachi ZeroCarbon and MUFG Bank have also entered into an MoU with Boreal Norge AS and its subsidiary Boreal Buss AS, one of Norway’s primary transport operators, providing transport services across several counties and employing around 3,000 employees across its fleet, which includes over 850 buses and 35 ferries. The parties will explore how they can support Boreal’s transition planning, de-risk operations, optimize services and strengthen competitiveness as concessions evolve.Jun Taniguchi, Senior Vice President and Executive Officer, CEO of Strategic SIB Business Unit, at Hitachi, Ltd. said:“We are delighted to advance this partnership which combines Hitachi’s deep expertise in social infrastructure and digital technologies with MUFG Bank, Ltd.’s financial strength to accelerate the transition to a decarbonized society. By improving the performance of assets such as batteries and charging infrastructure through Hitachi’s digital services led by HMAX, we can truly help customers optimize the total cost of ownership. This partnership embodies our One Hitachi approach, leveraging our diverse capabilities across the Group to support our customers in achieving their net-zero ambitions.”Masakazu Osawa, Senior Managing Executive Officer Chief Executive, Japanese Corporate & Investment Banking Business Unit of MUFG Bank, Ltd., said:“Building on MUFG’s Business Co‑Creation and Investment approach, this collaboration with Hitachi aims to create value through strategic partnerships that improve society and the environment. For the global EV market, our focus is not only on strengthening Hitachi’s leading position in Battery as a Service, but also on fostering a holistic value chain — including second‑ life battery markets — that supports the acceleration of electric mobility and the achievement of 2050 net‑zero targets. Together with our partners, we are committed to co‑creating sustainable businesses that become a driving force for progress worldwide.”Nikolai Knudsmoen Utheim, Group CEO, Boreal Norge AS said:“Our priority has always been to deliver first-class transport services to our customers, whether that’s on the road, rail or over water. In exploring how we can unlock the power of electrified fleets, we can not only deliver more sustainable operations, but upgrade our infrastructure and thread technology across our entire business model for more efficient, smart transport and energy management.”About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.About MUFGMitsubishi UFJ Financial Group, Inc. (MUFG) is one of the world’s leading financial groups. Headquartered in Tokyo and with over 360 years of history, MUFG has a global network with approximately 2,000 locations in more than 40 countries. The Group has about 150,000 employees and offers services including commercial banking, trust banking, securities, credit cards, consumer finance, asset management, and leasing. The Group aims to “be the world’s most trusted financial group” through close collaboration among our operating companies and flexibly respond to all of the financial needs of our customers, serving society, and fostering shared and sustainable growth for a better world. MUFG’s shares trade on the Tokyo, Nagoya, and New York stock exchanges. For more information, visit https://www.mufg.jp/english.About BorealBoreal is a leading mobility provider, operating buses, fast ferries, passenger ferries and trams in Norway and Sweden. We remain firmly committed to our societal mission of encouraging more people to travel collectively. At the same time, we are more than public transport. As the only company operating buses, ferries, fast ferries, trams and tourism services, we deliver integrated mobility solutions and travel experiences. Although Boreal is a young company in name, its heritage extends back more than 150 years. The company has around 3,000 employees and is headquartered in Stavanger, Norway. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The filing will follow a standard review timeline.Taletrectinib (marketed as IBTROZI® in the U.S. and Japan) is a highly selective, next-generation oral treatment for patients living with advanced ROS1+ NSCLC.1 In January 2026, Eisai and Nuvation Bio announced they had entered into an exclusive licensing and collaboration agreement in Europe and additional countries* outside the U.S., China and Japan to extend the global reach of taletrectinib. Following this filing to the EMA, additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories.Across Europe, nearly 400,000 people are diagnosed with lung cancer each year with NSCLC accounting for 80% of cases.2,3 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5“The validation of the MAA is a significant moment for patients in Europe with ROS1+ NSCLC,” said Terushige Iike, Chief Business Officer of Eisai Co., Ltd. “With its efficacy and safety profile, we believe taletrectinib has the potential to become a standard of care therapy for the thousands of patients living with this aggressive disease in Europe. We look forward to working closely with the EMA during the review process with the goal of making this treatment available to appropriate patients who urgently need targeted options.”The application is based on data from the two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib in patients globally.6,7 Results from a pooled analysis of the TRUST clinical program were published in the Journal of Clinical Oncology in April 20258, and Nuvation Bio anticipates near-term disclosure of updated data reflecting even longer patient follow-up, further building on the depth and durability of responses observed to date. Additionally, given the comprehensive nature of the taletrectinib clinical dataset and based on favorable feedback received at a pre-submission meeting with the CHMP Rapporteur and Co-Rapporteur, the accepted MAA will be considered to support full approval.“Having seen the meaningful impact taletrectinib has already made for patients with ROS1+ NSCLC in the U.S., China and Japan, we are thrilled to partner with Eisai and have an accepted MAA for review in Europe,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “This accepted filing represents an important milestone in our global development strategy and brings us one step closer to delivering this highly selective, next-generation oral therapy to more patients who need it in Europe and around the world.”In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®.* Eisai’s licensed territories: Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and IndiaAbout ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer.9 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5 About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain.10 The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.10,11About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com. 1About the TRUST Clinical ProgramThe TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 138 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs.6,7About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Nuvation BioNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).U.S. IndicationIBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ nonsmall cell lung cancer (NSCLC).IMPORTANT SAFETY INFORMATION FOR IBTROZI® (taletrectinib)1WARNINGS AND PRECAUTIONSHepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.ADVERSE REACTIONSAmong patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).DRUG INTERACTIONSStrong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI. OTHER CONSIDERATIONSPregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation. Please see accompanying full U.S. Prescribing Information.(1) Nuvation Bio Inc. IBTROZI (taletrectinib) US prescribing information. Available at: https://ibtrozipi.com/IBTROZI_taletrectinib-prescribing-information.pdf. Last accessed: March 2026(2) Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. Available here. Last accessed: March 2026(3) European Lung Foundation. Lung cancer. Available here. Last accessed: March 2026(4) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(5) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131. doi:10.1056/NEJMoa2302299. (6) ClinicalTrials.gov. A Study of AB-106 in Advanced NSCLC With ROS1 Fusion (NCT04395677). Available at: https://clinicaltrials.gov/study/NCT04395677 . Last accessed: March 2026(7) ClinicalTrials.gov. A single-arm Phase 2 study of taletrectinib in advanced ROS1-positive NSCLC (NCT04919811). Available at: https://clinicaltrials.gov/study/NCT04919811 . Last accessed: March 2026(8) Pérol M, A., et al. Taletrectinib in ROS1-positive non-small cell lung cancer: TRUST. Journal of Clinical Oncology, 43(16), 1920–1929. https://doi.org/10.1200/JCO-25-00275(9) Global Data. Diagnosed incident cases of non-small cell lung cancer across 8MM to reach 1.46 million in 2032, forecasts GlobalData. Available here. Last accessed: March 2026(10) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(11) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Nuvation Bio Inc.Kaitlyn Nealymedia@nuvationbio.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Nuvation Bio Inc.JR DeVitair@nuvationbio.comForward-Looking Statements of Nuvation Bio Inc.Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding taletrectinib’s therapeutic potential and the urgent need for new therapeutic options for patients with advanced ROS1+ NSCLC in Europe, our expectations that the MAA filing for taletrectinib will follow a standard review with a decision in 1H 2027 and be considered for full approval, plans for additional filings for the U.K., Canada and other regions included in Eisai’s licensed territories, and expectations for near-term disclosure of updated data. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on March 2, 2026 under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

(AsiaGameHub) -   AffPapa is rolling out four exclusive new categories for the AffPapa iGaming Awards 2026, redirecting part of the spotlight from companies to the individuals driving the industry’s progress. While the awards have historically focused on honoring brands in the iGaming sector, this year’s edition expands that scope to also highlight personal accomplishments and leadership contributions. The newly added categories for the AffPapa iGaming Awards 2026 are as follows: Woman Leader of the Year CEO of the Year Affiliate Manager of the Year Best Employer of the Year Designed to be more selective and targeted, these categories place a greater emphasis on individual contributors and workplace culture, rather than overall company performance. Levon Nikoghosyan, CEO at AffPapa, stated: Behind every high-performing company, there are always teams carrying out core work and keeping operations running smoothly. We wanted to shine more light on that side of the industry this year, as these are the people who also shape its future trajectory. The decision to launch these new categories aligns with the event’s newly adopted theme, “The Test of Time”, which centers on consistency, resilience, and long-term impact, recognizing those who have remained relevant while supporting the industry’s growth. Registration for the AffPapa iGaming Awards 2026 is still open, with affiliates, operators, and B2B providers invited to submit their brands for nomination, including for the new categories. Winners will be announced at the awards ceremony on the final day of the AffPapa Conference Madrid, held from May 18–20. Companies and industry professionals can sign up for the AffPapa iGaming Awards 2026 through the official event website. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   Cambodia is nearing the enactment of a specialized telecom fraud law—the first of its kind in the region—which could impose life imprisonment as a penalty. According to Koet Rith, Deputy Prime Minister and Minister of Justice, the Anti-Telecom Fraud Law has been approved by the cabinet and is now under review by the National Assembly’s legislative and judicial committee. Government officials state the law was drafted in response to the growing number of scams and fraudulent activities in the telecommunications sector and aims to prevent criminals from regrouping following recent crackdowns. Under the draft legislation, operators or managers of scam centers may face lengthy prison terms. Those who establish or run such facilities could be sentenced to 5 to 10 years in prison. However, if the operation involves unlawful detention, extortion, or homicide, the sentence could range from 30 years to life imprisonment. The bill will set penalties for those who recruit or train individuals for fraudulent operations and hold landlords and property owners responsible for leasing premises to such operations. The legislation will define offenses for five categories of individuals. This initiative follows multiple public remarks by Prime Minister Hun Manet, who emphasized that the government is undertaking a genuine and ongoing effort to address telecom fraud, not merely a superficial one. The Prime Minister has noted that this issue is not only a domestic problem but has also damaged Cambodia’s international reputation, meaning the reform carries political weight. The pace at which the bill is processed by relevant committee(s) to reach the National Assembly will shape the immediate next steps. The severity of life sentences and heavy fines for those involved in serious fraud cases underscores the government’s heightened efforts to shut down Cambodia’s top fraud hub and target its backers. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   South Africa’s gambling sector has been drawing significant attention recently due to the high volume of annual license issuances, according to new parliamentary statistics. A parliamentary response from Rise Mzansi MP Makashule Gana confirmed that 3,135 licenses were issued for the 2024/2025 financial year—marginally down from 3,174 in the prior year and slightly below 3,186 in 2022/2023. The approval of such a large number of licenses has raised questions about whether the government can adequately monitor the gambling industry’s growth. Most licenses were granted to limited payout machines and bookmakers, which account for the majority of the sector’s growth. Police have stated that oversight in the gambling sector is insufficient. Questions have been raised about whether provincial boards have the appropriate resources to consistently enforce regulations related to consumer protection, responsible gambling, and financial reporting. There is growing concern that oversight from provincial boards is inconsistent across provinces, with some boards having significant resources and others having very few. Police reported a total of 32,938 illegal gambling cases over the last five financial years, with approximately 100% originating from land-based gambling establishments. During the same period, 36 online gambling cases were reported, resulting in 39 arrests and 22 convictions. Due to these issues, many legislators are calling for increased coordination between national and provincial authorities. Several proposals have been made to improve This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   EveryMatrix has successfully enhanced its aggregation platform through a partnership with Eeze, enabling its global partners to access Eeze’s live dealer and RNG content portfolio. The two most significant new additions to EveryMatrix’s platform are the recently introduced Fusion Roulette and Eeze’s inaugural slot games. Bjorn Sjoberg, Chief Commercial Officer at EveryMatrix, said: We are delighted to incorporate Eeze’s complete product suite into our aggregation offering. With top-tier live products and an exciting lineup of RNG games in development, we are confident our clients will appreciate the distinctiveness these titles bring to the market. Mikko Hoglund, Partnership Manager at Eeze, added: Collaborating with EveryMatrix is a pivotal moment for us as we aim to introduce our games to a broader player network than ever. We have several exciting product launches planned for the coming months and are confident these games, along with our existing portfolio, will be well-received by EveryMatrix’s client base. Similarly, EveryMatrix has been expanding its footprint in the US market. Last month, it partnered with Ocean Casino Resort in New Jersey, making a vast selection of over 45,000 titles from more than 360 suppliers accessible to players on Ocean Resort’s online platform, betOcean, via EveryMatrix’s casino platform. This marked EveryMatrix’s fifth partnership in North America and third in the United States. The company currently holds licenses in Connecticut, Michigan, New Jersey, Pennsylvania, and West Virginia, as well as in Ontario, Canada. Its associates include bet365, BetPark Delaware North, and Pinnacle. Mark Burroughes, Chief Commercial Officer of Casino at EveryMatrix, said at the time: Collaborating with betOcean is a critical step in our growth strategy. Achieving a full aggregation integration in under four months, including regulatory approval, demonstrates our extensive expertise in delivering compliant content in the US. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   More than 17,000 individuals have signed onto a class action suit targeting Norsk Tipping, marking the biggest class action case ever recorded in Norway. Legal firm SANDS launched the action following confirmation that glitches in the Lotto and Eurojackpot draw systems had impacted participants' winning probabilities. The cutoff date for joining the legal action was February 16, 2026. Norway's gambling regulator reports that these malfunctions impacted numerous drawings carried out across several years. Lars Tormodsgard, a partner at SANDS, maintains that the issues caused players to face poorer chances than what was promoted, representing a critical defect in how these games functioned. Plaintiffs are demanding reimbursement for all wagers placed before the issue was discovered. Bets made during the affected timeframe stretching from 2015/2016 through 2025 span from minimal to substantial amounts. While the overall case value remains undetermined, the sheer number of participants suggests it could reach significant proportions. While Norsk Tipping has conceded that technical problems occurred, it rejects any legal responsibility. The company argues that the glitches only impacted supplementary draws and does not justify returning all stakes for every drawing. The operator has announced its intention to contest the claims in court. The lottery operator is also facing separate legal proceedings, alongside various regulatory penalties imposed in recent years that have accumulated to NOK 119 million (about $14 million) for assorted technical and operational breakdowns. This includes a NOK 46 million penalty specifically for drawing mistakes. Officials indicate this particular bug may have persisted for up to a decade, potentially giving organized betting groups a major advantage over solo players. Court proceedings are set to commence on August 25-26, 2016. The verdict will carry substantial financial consequences for Norsk Tipping and could establish a significant benchmark for addressing gambling industry mistakes within regulated markets. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   Playtech’s FY2025 results indicate that managing the restructuring and the sale of Snaitech proved challenging, leading to decreases in both revenue and earnings. Compared to FY2024, Total Group Revenue for FY2025 fell by $763.6 million (10%). Adjusted EBITDA decreased by $197 million (9%), which was slightly above initial forecasts thanks to better-than-anticipated operational performance in the US. Playtech also saw a decline in profitable operations, with post-tax profit from continuing operations dropping 28% to $44.2 million. The company reported a net loss attributable to operations of €169.5 million for the full year. However, total profit for the year reached €120.7 million when discontinued operations were included. The notable year-over-year difference in total profit stemmed from the absence of one-off gains that had been recorded in the previous fiscal year. Revenue from Playtech’s core B2B division fell by 9% to €688.3 million, and EBITDA fell by 36% to €141.4 million. These decreases were mainly driven by modifications to the Caliente agreement, which shifted earnings from revenue to investment income. If these changes are excluded, B2B revenue from regulated markets actually increased by 6%, accounting for more than 80% of total B2B revenue. After finalizing the €2.3 billion sale of Snaitech, Playtech’s financial standing has strengthened considerably, moving from a net debt position to a net cash position of €28.5 million. Alongside bolstering its finances, the company returned approximately €1.8 billion to shareholders via special dividends and share buybacks. The Snaitech deal has also realigned Playtech’s strategy to focus more on B2B and lower its overall exposure. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   Bede Gaming has been granted provisional approval by the Alberta Gaming, Liquor and Cannabis (AGLC) board for a one-year supplier license. This authorization positions the company as a key participant in Alberta’s forthcoming fully regulated online gambling market, slated for launch later this year. This license, designated for iGaming Goods or Services Suppliers, permits Bede Gaming, a subsidiary of the German Merkur Group, to provide its platform and services to operators preparing for the launch of Alberta’s iGaming market. By securing its status as one of the earliest licensed suppliers in the province, Bede Gaming is poised to capitalize on the initial business opportunities presented by Alberta’s market opening. The company's technology stack, which is SOC 2 certified, includes its proprietary software alongside over 150 third-party integrations. Bede Gaming aims to facilitate market entry for its partners and support their long-term growth. Although the province is scheduled to begin registering operators in January 2026, some industry analysts anticipate that the market's growth trajectory could mirror that of Ontario's iGaming sector. Furthermore, Alberta is increasingly recognized as a significant entry point for international operators into the North American market. Colin Cole-Johnson, Chief Executive Officer at Bede Gaming, stated: Bede is pleased to have received conditional regulatory approval to operate in Alberta, which places us in an excellent position to assist operators with their upcoming expansions within the province. We have a sustained commitment to the Canadian iGaming industry, and I am enthusiastic about the promising opportunities that lie ahead in this new market. As one of the first applicants to be formally recognized by the regulator, Bede offers a genuinely localized service to its partners, and the fact that they are SOC 2 certified will enable them to commence operations immediately upon readiness for launch. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

The Frst New Leo Liner "L00 Series"TOKYO, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed delivery of the first trainsets L00 Series ("Leo-kei") trains (4 cars per trainset, total 12 cars) ordered by Seibu Railway Co., Ltd. for its Yamaguchi Line, an automated guideway transit (AGT) system. Commercial operation of the first train began on March 27th. That same day, Seibu Railway held a commemorative ceremony for the start of commercial operation, attended by Tokorozawa City Mayor Masatoshi Onozuka and Higashimurayama City Mayor Takashi Watanabe.The new L00 Series are being manufactured at MHI's Mihara Machinery Works in Hiroshima Prefecture, and are scheduled to be delivered sequentially by FY2027. The seating arrangement has been changed from the bench seats used in the existing 8500 Series vehicles to longitudinal seats to increase transport capacity to BELLUNA DOME baseball stadium and Seibuen Amusement Park. To meet diverse passenger needs, wheelchair spaces, children's seats, and in-car information displays have been installed to enhance convenience.In addition, the new trains incorporate many unique specifications designed by MHI especially for AGT system vehicles, including aluminum bodyshells, the MHI bogie,(1), a ceiling duct air conditioning system,(2) and A-MVCS (Advanced Mitsubishi Vehicle Control System). The A-MVCS in particular, in addition to the vehicle control function, has monitoring and commissioning functions for each piece of on-board equipment, allowing it to flexibly meet the needs of railway operators.Further, a large glass window has been installed in the partition wall between the driver's cab and the children's seat, allowing children to enjoy the view from the front window and driver's seat, enhancing the sense of excitement for passengers.This AGT system utilizes rubber tires for a smooth ride and low noise. In addition, as a type of clean mobility with low CO2 emissions, the system has a reduced environmental impact, supporting the realization of a decarbonized and energy-efficient world. The adoption of vehicles that combine excellent design and environmental performance also enhances the impression of the surrounding facilities.Going forward, MHI Group will continue to strive for technological innovation, and through services that safely and comfortably transport people and goods, contribute to the development of public transport that supports the lives of people around the world.(1) A bogie developed by MHI for AGT systems. It is compatible with general rubber tire operation for AGTs.(2) A system that directs air through ducts behind the ceiling to provide air conditioning.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

(AsiaGameHub) -   A significant probe in Chile has identified 910 public employees who engaged in casino gambling despite a legal prohibition. This finding was detailed in the ‘Twentieth Consolidated Circularized Information Report’ released by the Office of the Comptroller General of the Republic (CGR). The breach was uncovered through a data comparison of public servant records from the Superintendency of Gambling Casinos. The audit focused on personnel responsible for managing or protecting state funds, revealing gambling activities that violate national statutes. According to the findings, these employees wagered more than 11.49 billion Chilean pesos between January 2024 and June 2025. Chilean legislation is very specific regarding these restrictions. Under Law 19.995, Article 10 (B): Individuals who, by virtue of their roles, manage or oversee public finances are strictly prohibited from participating in any form of casino gambling, whether directly or via intermediaries. The rationale for this ban is clearly stated: This restriction aims to protect public assets and ensure that those in positions of trust are not exposed to environments that might interfere with their professional obligations. The data indicates that a small minority was responsible for the bulk of the gambling. Specifically, 181 of the 910 identified officials accounted for 96.8% of the total wagers, totaling over 11.118 billion pesos. Furthermore, just 20 individuals were responsible for 5.392 billion pesos in bets. This group included a Chilean Air Force member who allegedly wagered 1.04 billion pesos. The scale of these transactions has sparked concerns regarding potential criminal conduct beyond administrative violations. The CGR remarked: The substantial volume of bets placed by the most active gamblers suggests that criminal offenses may have occurred. Consequently, the CGR has requested that the State Defense Council and the Public Prosecutor’s Office evaluate the necessity of launching criminal investigations. Additionally, 371 government agencies associated with the individuals involved have been notified. These include the Air Force, the national and investigative police, the Treasury, and various municipal governments. The CGR directed: These organizations are required to investigate the conduct of the implicated staff and implement appropriate disciplinary actions, which may include termination of employment. The names of the 910 officials have also been shared with the Superintendency of Gambling Casinos, allowing the regulator to pursue further oversight or legal action as required. This situation underscores the difficulties authorities face in enforcing gambling bans for public servants and could have major implications for government transparency and accountability in Chile. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   Building on its progressive stance towards online gambling and blockchain regulation, Malta is now initiating an exploration of the optimal ways to regulate prediction markets. Drawing on insights from regulatory analyses in other jurisdictions, the Maltese government is preparing an initiative to establish a framework for overseeing prediction markets. Prediction markets facilitate the trading of outcomes for real-world events, such as elections, economic indicators, and sporting events. This sector has expanded significantly in recent years, particularly in the United States. Platforms like Kalshi and Polymarket have seen remarkable growth, with industry trading volume projected to reach hundreds of millions of dollars between 2023 and 2025. The European Union currently lacks a unified regulatory framework for prediction markets. Member states have adopted varying approaches; some permit these markets, while others are still determining their regulatory classification—whether as a gambling service, a financial instrument, or a hybrid of both. Malta's move to develop a regulatory structure aligns with its broader objective of becoming a hub for emerging digital sectors like online gaming and blockchain. This initiative also aims to offer legal clarity for operators seeking to enter the European market. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

KAWASAKI, Japan, Mar 27, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced the development of a world-leading, high-sensitivity and high-resolution infrared sensor to expand monitoring capabilities in the defense and disaster prevention fields. This sensor is a Type-II superlattice (T2SL) infrared sensor with over 1 million pixels, capable of detecting both mid-wavelength infrared (MWIR) and long-wavelength infrared (LWIR) light. Its high-sensitivity allows it to clearly capture minute thermal differences of 0.05°C or less, enabling high-precision monitoring day and night. This over 1-megapixel dual-band T2SL infrared sensor is the first of its kind in the world.The newly developed technology boasts dramatically enhanced detection and identification performance, with applications spanning a wide range of fields. For example, when applied to optical sensor systems mounted on satellites or aircraft, it can contribute to the creation of new value across diverse areas, including early assessment of disaster situations and environmental monitoring.Integrating this sensor into monitoring devices for defense and disaster prevention enables accurate detection of thermal changes, such as identifying precursors to human activity or object movement, locating people during disasters, detecting early forest fires, and monitoring tsunamis. This contributes to improving information gathering capabilities and strengthening defense and disaster prevention. Additionally, by visualizing thermal distribution and changes over time with exceptional precision, the sensor is anticipated to play a vital role in tackling societal issues like infrastructure inspection and problems with analytical equipment, while also driving progress in scientific research.This technology was developed under contract as part of the "PROTOTYPE OF WIDE BAND AND HIGH RESPONSIVITY PHOTO-DETECTORS" from Acquisition Technology & Logistics Agency (ATLA), Japan Ministry of Defense, to which Fujitsu has completed delivery of the prototype sensor.Starting in fiscal year 2026, Fujitsu plans to leverage the manufacturing technology of this sensor to develop new products and market them for use in monitoring cameras.BackgroundIn the security sector, which underpins a safe and secure society, there is a demand for advanced sensing technologies that can detect various threats early and accurately capture their precursors. However, with the diversification of monitoring scenarios and the increasing complexity of targets, there is a need for even higher resolution sensors and improved identification capabilities through simultaneous detection of multiple wavelengths. The ATLA initiated a research prototype project to establish technology that enables target detection and identification over longer distances and wider areas than existing systems. Fujitsu, which has developed and mass-produced high-sensitivity infrared sensors, was awarded this project and has now successfully completed its development.Overview of the developed sensorInfrared sensors capture infrared radiation spontaneously emitted by objects with heat, visualizing their surface temperature distribution. Fujitsu has leveraged the characteristics of T2SL, a compound semiconductor with a superlattice structure that allows for material property control, to develop a unique dual-band sensor. The superlattice structure, where different semiconductor materials are layered at the nanometer (one billionth of a meter) level, offers high sensitivity, as well as excellent control over detection wavelengths and manufacturability. By selecting a combination of semiconductor materials with a large energy offset in their band structure (i.e., Type-II Superlattice, T2SL), it is possible to detect infrared light, which has lower energy than visible light.This sensor can detect MWIR and LWIR wavelength bands, with high-sensitivity capable of detecting temperature differences of 0.05°C or less. By simultaneously detecting two wavelengths with a single pixel, it can accurately detect and identify targets that would otherwise be obscured by background noise during detection with single-wavelength sensors. Furthermore, by advancing miniaturization of elements through the development of manufacturing processes and mounting technologies suitable for delicate T2SL materials, Fujitsu has achieved high-resolution with over 1 million pixels, enabling the capture of more distant targets.This infrared sensor, simultaneously achieving high-sensitivity, high-resolution, and dual-band detection, is suitable for monitoring applications in defense, disaster prevention, and other fields requiring high discrimination performance.Furthermore, this world-first technology from Fujitsu will drive further advancements in the sensitivity, multi-band and high-resolution capabilities of conventional infrared sensors, enabling a diverse range of product developments.Figure: Dual-band T2SL infrared sensor and example imagesAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

(AsiaGameHub) -   Splinterlands has forged an official partnership with AtomicHub with the objectives of reviving and upgrading the WAX bridge, boosting visibility for its card NFTs, and simplifying cross-chain access for collectors and players. Splinterlands has previously supported WAX transfers, and its official documentation still lists WAX as one of its longest-standing partners. Good to Know AtomicHub has confirmed that it facilitates NFT trading across WAX, Vaulta, XPR Network, Polygon, Immutable, and Avalanche. Splinterlands’ cards have long been eligible for trading outside of the in-game marketplace, including on WAX via AtomicHub. The immediate priority is a more streamlined WAX bridge and improved discoverability for Splinterlands’ digital assets across marketplaces. Splinterlands and AtomicHub Revive a Familiar Connection Instead of building a new system from scratch, the two parties are building upon an existing prior link. Splinterlands and AtomicHub previously collaborated on a WAX bridge that allowed assets to be transferred for secondary market trading. The current plan is to modernize this existing setup and make transfers more seamless for users seeking additional places to buy and sell their cards. For Splinterlands, liquidity is the central focus. A trading card game’s economy functions more effectively when players can set clear prices for their cards, trade at a faster pace, and connect with buyers across multiple blockchains. AtomicHub provides a broader storefront for this effort, as it already operates across several blockchains and has a long track record in NFT trading. This partnership also aligns with Splinterlands’ core operations. Launched in 2018, the game runs on the Hive blockchain and revolves around player-owned cards that can be traded or rented out. Splinterlands also highlights tournament rewards and a card rental model in its official support materials, making access to external marketplaces far more relevant than it would be for a closed-game economy. Looking further ahead, both teams have plans that extend beyond the WAX blockchain. AtomicHub’s multi-chain support gives Splinterlands a path to reach a wider audience of collectors if deeper integrations are implemented. No timelines or additional blockchains have been detailed as of yet, so the most concrete deliverable for now is the upgraded bridge. FAQ What is the main goal of the Splinterlands and AtomicHub partnership? The primary goals of this partnership are to enhance liquidity for Splinterlands’ assets, upgrade the WAX bridge, and expand access to card trading across blockchain ecosystems. Did Splinterlands and AtomicHub work together before? Yes. Splinterlands previously operated a WAX bridge and has had a presence for its cards on AtomicHub for a long time. Why does liquidity matter for Splinterlands cards? Improved liquidity leads to simpler price discovery, more active trading, and more accessible entry points for players looking to build decks without overpaying. This is an inference based on how Splinterlands’ cards are traded and rented within its native ecosystem. Which blockchains does AtomicHub support right now? AtomicHub has stated that it supports NFT trading across WAX, Vaulta, XPR Network, Polygon, Immutable, and Avalanche. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   Netflix has once again increased prices for all its streaming plans, including the ad-supported tier, Standard plan, and Premium plan. The revised rates became effective for new members on March 26, with existing subscribers set to experience the changes at a later date. Good to Know The ad-supported plan now costs $8.99 per month, an increase from $7.99. The Standard plan is now priced at $19.99, while the Premium plan costs $26.99. Existing members will receive an email approximately one month before the new price is applied to their account. Netflix Increases Prices Once More Netflix did not launch any new products alongside this price hike. Instead, it quietly updated plan pricing and additional member fees. The ad-supported tier saw a $1 increase, the ad-free Standard plan went up by $2, and the Premium plan also rose by $2. Additional member fees now stand at $7.99 for ad-supported plans and $9.99 for ad-free plans. Android Authority was the first to spot the revised pricing. Netflix later stated that these changes reflect its ongoing investment in its entertainment lineup and service quality. New members now see the updated rates immediately, while current subscribers will transition to the higher pricing over the next few months. The company last raised prices in January 2025. Since then, Netflix has continued to add live content and new product features, and its investor materials have also highlighted pricing as a key part of revenue growth. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   Google has extended its Live Translate feature— a real-time translation tool for headphones— to iPhones and additional countries. This update means the tool is now functional on both iOS and Android across 12 markets, such as Thailand, Japan, the UK, France, Germany, and Spain. Good to Know Live Translate is now available in the U.S., India, Mexico, Germany, Spain, France, Nigeria, Italy, the UK, Japan, Bangladesh, and Thailand. This feature is compatible with any set of headphones and offers support for over 70 languages. Google has also rolled out Search Live globally to regions where AI Mode is accessible. Google Extends Live Translate Beyond Android Devices Google is transforming its Translate app into a more useful tool for travel and conversations. Using Live Translate, users can connect their headphones, launch the app, select the feature, and listen to real-time translated speech while preserving the original speaker’s tone and pacing more closely. According to Google, this feature is powered by Gemini. This expanded rollout is significant because the feature was previously restricted to Android devices in just three countries: the U.S., India, and Mexico. Now it’s available on both major mobile platforms across a larger number of markets, strengthening Google Translate’s appeal to consumers for travel, family interactions, and daily language assistance. Google also revealed this update on the same day as a wider expansion of Search Live. That feature is now being rolled out globally in languages and regions where AI Mode is available, expanding another Gemini-integrated experience far beyond its initial reach. For Google, the larger strategy seems evident: to make Gemini-powered tools feel helpful in everyday situations, not just within chatbots or search interfaces. This observation is inferred from the timing of both rollouts and how Google is positioning these features across Translate and Search. FAQ What Exactly Is Google Live Translate? It’s a feature within Google Translate that allows users to listen to real-time translations via their headphones. Is Google Live Translate Now Accessible on iPhones? Yes. Google stated that the feature has officially launched on iOS. Which Countries Currently Offer Support for Live Translate? The feature is now available in the U.S., India, Mexico, Germany, Spain, France, Nigeria, Italy, the UK, Japan, Bangladesh, and Thailand. How Many Languages Does Live Translate Work With? According to Google, it supports over 70 languages. How Can Users Access Live Translate? Users can access it by opening the Google Translate app, connecting their headphones, and tapping on the Live Translate feature. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.

(AsiaGameHub) -   Officials in Ireland have successfully entered a previously inaccessible Bitcoin wallet associated with a significant criminal forfeiture. This development allowed the Criminal Assets Bureau (CAB) to retrieve approximately 500 Bitcoin, valued at about $35.5 million based on current market rates. Good to Know The unlocked wallet is part of a group of 12 seized in 2019. The entire collection consists of roughly 6,000 Bitcoin. Technical assistance and decryption tools were provided by Europol. Ireland Successfully Accesses One Wallet in Ongoing Bitcoin Forfeiture Case For a long period, the confiscated Bitcoin remained out of reach due to missing private keys. This situation has partially resolved, as the Irish Times reported that CAB, in collaboration with Europol, managed to open a single wallet containing 500 Bitcoin. The assets are linked to the case of Clifton Collins, a convicted drug dealer. The origins of the case date back to 2011 and 2012, when Collins used profits from cannabis sales to purchase Bitcoin. He distributed the funds across 12 separate wallets but recorded the security details on a document that was subsequently lost. Previous reports indicated the codes were concealed in a fishing rod container that went missing during a property clearance. While the specific methods used to open the wallet remain undisclosed, Irish officials noted that Europol contributed sophisticated technical knowledge and decryption capabilities to the effort. Despite this success, the majority of the seized cryptocurrency remains inaccessible. Current estimates suggest the remaining balance is worth hundreds of millions of euros.For cryptocurrency holders, this event highlights the fundamental principle of digital asset custody: possessing the private keys is essential for control. Once these details are lost, regaining access is typically impossible without specialized forensic intervention. Ireland's recent success in recovering a portion of the funds suggests a breakthrough in their investigative approach. FAQ How much Bitcoin was recovered? Authorities gained access to 500 Bitcoin from one of the seized wallets. How many wallets were involved? The total holdings were distributed among 12 wallets. Who was the Bitcoin associated with? The assets were tied to Clifton Collins, an Irish drug trafficker.Why was the cryptocurrency inaccessible for so long? The login credentials were lost after being stored in a fishing rod case that was misplaced. Who assisted in the recovery? Europol provided the necessary technical and decryption support for the operation. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.